MetaCap

Capricor Therapeutics (CAPR) vs CorMedix (CRMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed CorMedix (CRMD) over the past year, gaining 32.0% versus a loss of 45.6%. Over five years, CAPR leads with a +122.6% price change compared with +3.9% for CRMD. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $419.2 million), about 1.1 times the size, while CorMedix is growing revenue faster (+617.0% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%CRMD-45.56%
+543%+231%-82%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%CRMD+2.73%
+1009%+457%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus CRMD key metrics
MetricCAPRCRMD
Share price$7.59$5.27
Market cap$441.30M$419.16M
1-day change+0.80%+3.74%
YTD return-73.70%-54.69%
1-year return+32.00%-45.56%
5-year return+122.58%+3.94%
P/E ratio (TTM)—8.23
Forward P/E—15.06
EPS (TTM)$-2.65$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$311.71M
Revenue growth (YoY)-100.00%+617.03%
Net income (latest FY)$-105.04M$163.06M
Gross margin—88.46%
Operating margin—48.17%
Net margin—52.31%
52-week high$40.37$13.02
52-week low$2.96$4.47
Distance from 52-week high-81.20%-59.52%
Analyst consensusbuybuy
Avg. price target upside+259.03%+161.86%
Average volume4.73M1.44M
Shares outstanding58.14M79.54M
Employees231191
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed CRMD by 77.6 percentage points over the past year.
  • CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -100.00%).

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

CAPR vs CRMD FAQ

Which is bigger, Capricor Therapeutics or CorMedix?

Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $419.16M for CorMedix (CRMD).

Which stock has performed better over the past year, CAPR or CRMD?

CAPR returned +32.00% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and CorMedix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons